Gemcitabine and Vinorelbine Combination Chemotherapy in Anthracycline- and Taxane-pretreated Advanced Breast Cancer
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: Anthracycline and taxanes are effective agents in advanced breast cancer and prolong survival times. Some patients achieve prolongation of life with capecitabine, gemcitabine, or vinorelbine, even after failure of both anthracycline and taxanes. We analyzed the efficacy and toxicity of gemcitabine and vinorelbine combination chemotherapy in anthracycline- and taxane-pretreated advanced breast cancer. Materials and Methods: The medical records of anthracycline- and taxane-pretreated metastatic breast cancer patients who received gemcitabine and vinorelbine combination chemotherapy at the Seoul National University Hospital were reviewed. Gemcitabine (1,000 mg/m²) and vinorelbine (25 mg/m²) were administered intravenously on days 1 and 8 every 3 weeks. Results: Between 2000 and 2006, 57 patients were eligible (median age, 45 years), and the median number of previous chemotherapy regimens was 3 (range, 1∼5). The overall response rate was 30% (95% CI, 18.1∼ 41.9), and the disease control rate was 46% (PR, 30%; SD, 16%). The median duration of follow-up was 33.4 months, the median time-to-progression (TTP) was 3.9 months, and the median overall survival was 10.8 months. None of thepatients with patients with anthracycline and taxane primary resistance showed a response and the median TTP for these patients was significantly shorter than that of other patients (1.9 vs. 4.4 months; p=0.018). Although the efficacy was unsatisfactory in patients with both anthracycline and taxane primary resistance, gemcitabine and vinorelbine combination chemotherapy showed comparable efficacy in anthracyclineand/ or taxane-sensitive patients and the patients with secondary resistance, even after failure of second-line therapy. Grade 3/4 hematologic toxicities included neutropenia (18.1%) and febrile neutropenia (0.3%), and non-hematologic toxicities were tolerable. Conclusion: Gemcitabine and vinorelbine combination chemotherapy in anthracycline- and taxane-pretreated advanced breast cancer was effective and tolerable.
Abstract
Purpose: Anthracycline and taxanes are effective agents in advanced breast cancer and prolong survival times. Some patients achieve prolongation of life with capecitabine, gemcitabine, or vinorelbine, even after failure of both anthracycline and taxanes. We analyzed the efficacy and toxicity of gemcitabine and vinorelbine combination chemotherapy in anthracycline- and taxane-pretreated advanced breast cancer. Materials and Methods: The medical records of anthracycline- and taxane-pretreated metastatic breast cancer patients who received gemcitabine and vinorelbine combination chemotherapy at the Seoul National University Hospital were reviewed. Gemcitabine (1,000 mg/m²) and vinorelbine (25 mg/m²) were administered intravenously on days 1 and 8 every 3 weeks. Results: Between 2000 and 2006, 57 patients were eligible (median age, 45 years), and the median number of previous chemotherapy regimens was 3 (range, 1∼5). The overall response rate was 30% (95% CI, 18.1∼ 41.9), and the disease control rate was 46% (PR, 30%; SD, 16%). The median duration of follow-up was 33.4 months, the median time-to-progression (TTP) was 3.9 months, and the median overall survival was 10.8 months. None of thepatients with patients with anthracycline and taxane primary resistance showed a response and the median TTP for these patients was significantly shorter than that of other patients (1.9 vs. 4.4 months; p=0.018). Although the efficacy was unsatisfactory in patients with both anthracycline and taxane primary resistance, gemcitabine and vinorelbine combination chemotherapy showed comparable efficacy in anthracyclineand/ or taxane-sensitive patients and the patients with secondary resistance, even after failure of second-line therapy. Grade 3/4 hematologic toxicities included neutropenia (18.1%) and febrile neutropenia (0.3%), and non-hematologic toxicities were tolerable. Conclusion: Gemcitabine and vinorelbine combination chemotherapy in anthracycline- and taxane-pretreated advanced breast cancer was effective and tolerable.
참고문헌 (24)
- Ahn SH, "Clinical characteristics of breast cancer patients in Korea in 2000", Arch Surg, 139, pp.27~30 (2004)
- Winer EP, "Cancer: principles and practice of oncology", pp.1651~717 (2004), Williams and Wilkins
- Kataja VV., "ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of locally recurrent or metastatic breast cancer", Ann Oncol, 16, pp.10~2 (2005)
- Plunkett W., "Gemcitabine: preclinical pharmacology and mechanisms of action", Semin Oncol, 23, pp.3~15 (1996)
- Carmichael J., "Advanced breast cancer: a phase II trial with gemcitabine", J Clin Oncol, 13, pp.2731~6 (1995)
- Potier P., "The synthesis of navelbine prototype of a new series of vinblastine derivatives", Semin Oncol, 16, pp.2~4 (1989)
- Weber BL, "Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer", J Clin Oncol, 13, pp.2722~36 (1995)
- Herbst RS, "Gemcitabine and vinorelbine in patients with advanced lung cancer: Preclinical studies and report of a phase I trial", Cancer Chemother Pharmacol, 48, pp.151~9 (2001)
- Donadio M., "Gemcitabine and vinorelbine as second-line treatment in patients with metastatic breast cancer: A phase II study", 52, pp.147~52 (2003)
- Mariani G., "Phase I", II study of gemcitabine in association with vinorelbine for metastatic breast cancer, 2001, pp.70, 163~9
- Nicolaides C., "Gemcitabine and vinorelbine as second-line treatment in patients with metastatic breast cancer progressing after first-line taxane-based chemotherapy: A phase II study conducted by the hellenic cooperative oncology group", Ann Oncol, 11, pp.873~5 (2000)
- Rossi E., "Is gemcitabine plus vinorelbine active in second-line chemotherapy of metastatic breast cancer? A single-center phase 2 study", Oncology, 64, pp.479~80 (2003)
- Therasse P., "guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada", J Natl Cancer Inst, 92, pp.205~16 (2000)
- Trotti A., "CTCAE version 3.0: development of a comprehensive grading system for the adverse effects of cancer treatment", Seminars in Radiation Oncology, 13, pp.176~81 (2003)
- Grindey GB, "Cytotoxicity and antitumor activity of 2', 2'-difluorodeoxycytidine (Gemcitabine)", Cancer Invest, 8, pp.313~ (1990)
- Binet S., "In situ analysis of the action of navelbine on various types of microtubules using immunofluorescence", Semin Oncol, 16, pp.5~8 (1989)
- Ravdin PM, "Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer", J Clin Oncol, 13, pp.2879~85 (1995)
- Valero V., "Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer", J Clin
- Verschraegen CF, "Docetaxel for patients with paclitaxel-resistant mullerian carcinoma", J Clin Oncol, 18, pp.2733~89 (2000)
- Pivot X., "A unified definition of clinical anthracycline resistance breast cancer", Brit J Cancer, 82, pp.529~34 (2000)
- Burris H III, "Phase II trial of trastuzumab followed by weekly paclitaxel", carboplatin as first-line treatment for patients with metastatic breast cancer, 2004, pp.22, 1621~9
- Tedesco KL, "Docetaxel combined with trastuzumab is an active regimen in HER-2 3＋ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multiinstitutional phase II trial", J Clin Oncol, 22, pp.1071~7 (2004)
- O'Shaughnessy JA, "Phase II study of trastuzumab plus gemcitabine in chemotherapy-pretreated patients with metastatic breast cancer", Clin Breast Cancer, 5, pp.142~7 (2004)
- Chan A., "A review of the use of trastuzumab (Herceptin) plus vinorelbine in metastatic breast cancer", Ann Oncol, 18, pp.1152~8 (2007)